New insider activity at Xencor ( (XNCR) ) has taken place on December 23, 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xencor has seen notable insider selling activity, with two top executives executing sizable stock transactions. Senior Vice President and Chief Scientific Officer John Desjarlais sold 73,367 shares of Xencor stock in a move totaling $1,153,329. In a separate transaction, President and CEO Bassil Dahiyat sold 114,377 shares, generating proceeds of $1,796,862. These trades by key leaders highlight significant recent activity in Xencor’s executive ranks.
Recent Updates on XNCR stock
In the last 24 hours, Xencor (XNCR) has seen fresh analyst attention and incremental positive news flow tied mainly to its pipeline and intellectual property. Barclays increased its price expectations for the stock as part of a broader 2026 biotechnology sector reassessment, reflecting a more constructive long-term view on the space rather than a company-specific earnings event. Truist initiated coverage citing encouraging early data from Xencor’s TL1A program that suggest sustained target engagement, and highlighting the company’s broader immunology and inflammation pipeline, which is underpinned by its established T‑cell engager technology and prior validation from its oncology work (including xaluritamig). Separately, Xencor announced issuance of a new U.S. patent that extends protection for its Xtend Fc domain used in C5‑targeting antibodies, lengthening the royalty stream it expects from Ultomiris and reinforcing visibility into future partnered revenue. The combination of extended IP-derived cash flows and growing confidence in the company’s pipeline appears to be the core rationale behind recent positive adjustments to analysts’ outlooks, though specific price moves in the stock over the period were not detailed in the articles.
Spark’s Take on XNCR Stock
According to Spark, TipRanks’ AI Analyst, XNCR is a Neutral.
Xencor’s overall stock score is driven by strong technical analysis and positive corporate events, indicating potential growth in its oncology pipeline. However, financial performance and valuation concerns, particularly negative profitability and a negative P/E ratio, weigh down the score.
To see Spark’s full report on XNCR stock, click here.
More about Xencor
YTD Price Performance: -32.87%
Average Trading Volume: 1,072,139
Technical Sentiment Signal: Buy
Current Market Cap: $1.11B